<DOC>
	<DOCNO>NCT01863732</DOCNO>
	<brief_summary>This 3-year extension study aim make available treatment secukinumab prefilled syrinx ( PFS ) patient ankylose spondylitis take part phase III study CAIN457F2305 , define `` core study '' , well generate additional data sustainability clinical benefit , safety tolerability long-term administration secukinumab .</brief_summary>
	<brief_title>Extension AS : Sustainability Benefits , Safety Tolerability</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>patient complete `` core study '' CAIN457F2305 , indication treatment extension . history hypersensitivity secukinumab drug similar chemical class , use investigational drug secukinumab `` core study '' CAIN457F2305 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AIN457 , ankylose spondylitis , chronic inflammatory disease , inflammatory back pain , PFS , pre-filled syringe , secukinumab , self-injection</keyword>
</DOC>